Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 543

1.

Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.

Pezzetta E, Stupp R, Zouhair A, Guillou L, Taffé P, von Briel C, Krueger T, Ris HB.

Eur J Cardiothorac Surg. 2005 Jun;27(6):1092-8. Epub 2005 Apr 18. Erratum in: Eur J Cardiothorac Surg. 2005 Aug;28(2):368.

PMID:
15896624
2.

Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.

Kumar P, Herndon J 2nd, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.

Cancer. 1996 Jun 1;77(11):2393-9.

3.

Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.

Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, Coosemans W, Lerut T.

Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6.

PMID:
19502079
4.

Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.

Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, Hausner P, Krasna M.

Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. Review.

PMID:
15464470
5.

The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.

Milman S, Kim AW, Warren WH, Liptay MJ, Miller C, Basu S, Faber LP.

Ann Thorac Surg. 2009 Sep;88(3):945-50; discussion 950-1. doi: 10.1016/j.athoracsur.2009.05.084.

PMID:
19699925
6.

Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection.

Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J Jr, Fossella FV, Allen P, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):204-12.

PMID:
14697440
7.

Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging.

Kirn DH, Lynch TJ, Mentzer SJ, Lee TH, Strauss GM, Elias AD, Skarin AT, Sugarbaker DJ.

J Thorac Cardiovasc Surg. 1993 Oct;106(4):696-702.

PMID:
8412265
8.

Postoperative adjuvant therapy for stage II non-small-cell lung cancer.

Park JH, Shim YM, Baek HJ, Kim MS, Choe DH, Cho KJ, Lee CT, Zo JI.

Ann Thorac Surg. 1999 Nov;68(5):1821-6.

PMID:
10585065
9.

[Multimodal treatment of non small cell lung cancer].

Stoelben E, Digel W, Henke M, Passlick B.

Zentralbl Chir. 2006 Apr;131(2):110-4. German.

PMID:
16612776
10.

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G; European Organisation for Research and Treatment of Cancer-Lung Cancer Group..

J Natl Cancer Inst. 2007 Mar 21;99(6):442-50.

PMID:
17374834
11.

Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.

Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):108-13.

12.

Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.

Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F.

Eur J Cardiothorac Surg. 2008 May;33(5):829-36. doi: 10.1016/j.ejcts.2008.01.063. Epub 2008 Mar 25.

PMID:
18367406
13.

Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer.

Grossi F, Pennucci MC, Serrano J, Frola C, Mereu C, Scolaro T, Ratto GB, Tixi L, Ardizzoni A.

Anticancer Res. 2002 Nov-Dec;22(6B):3519-24.

PMID:
12552949
14.

Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.

Jaklitsch MT, Herndon JE 2nd, DeCamp MM Jr, Richards WG, Kumar P, Krasna MJ, Green MR, Sugarbaker DJ.

J Surg Oncol. 2006 Dec 1;94(7):599-606.

PMID:
17039491
15.

Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).

Ma Q, Liu D, Guo Y, Shi B, Song Z, Tian Y.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):342-8. doi: 10.3779/j.issn.1009-3419.2010.04.14.

16.

Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.

Stefani A, Alifano M, Bobbio A, Grigoroiu M, Jouni R, Magdeleinat P, Regnard JF.

J Thorac Cardiovasc Surg. 2010 Aug;140(2):356-63. doi: 10.1016/j.jtcvs.2010.02.018. Epub 2010 Apr 9.

17.

Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).

Lee SW, Choi EK, Chung WK, Shin KH, Ahn SD, Kim JH, Kim SW, Suh C, Lee JS, Kim WS, Kim DS, Kim DK, Park SI, Sohn KH.

Lung Cancer. 2002 Jul;37(1):65-71.

PMID:
12057869
18.

Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC).

De Candis D, Stani SC, Bidoli P, Bedini VA, Potepan P, Navarria P, Aglione S, Bajetta E.

Am J Clin Oncol. 2003 Jun;26(3):265-9.

PMID:
12796598
19.

Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).

Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E 3rd, Sugarbaker DJ.

Lung Cancer. 1997 May;17(1):147-61.

PMID:
9194034
20.

Surgery after multimodality treatment for non-small-cell lung cancer.

Stamatis G, Eberhard W, Pöttgen C.

Lung Cancer. 2004 Aug;45 Suppl 2:S107-12.

PMID:
15552790

Supplemental Content

Support Center